Prior infection with Type A Francisella tularensis antagonizes the pulmonary transcriptional response to an aerosolized Toll-like receptor 4 agonist

BMC Genomics

Volumn 16, Issue 1, 2015, Pages

  Walters, Kathie Anne ^a   Olsufka, Rachael ^b   Kuestner, Rolf E ^a   Wu, Xiagang ^a   Wang, Kai ^a   Skerrett, Shawn J ^b   Ozinsky, Adrian ^a  

^a INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; FORKHEAD TRANSCRIPTION FACTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; HEPATOCYTE NUCLEAR FACTOR 3BETA; INTERFERON REGULATORY FACTOR 1; MYOCYTE ENHANCER FACTOR 2; TOLL LIKE RECEPTOR 4; AEROSOL; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; CEBPA GENE; CELL MIGRATION; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; FOX03 GENE; FOXA1 GENE; FOXA2 GENE; FOXD1 GENE; FOXD3 GENE; FOXF2 GENE; FOXL1 GENE; FOXQ1 GENE; GENE; GENE ONTOLOGY; GENE REPRESSION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; INFLAMMATION; INNATE IMMUNITY; IRF1 GENE; MALE; MEF2 GENE; MOUSE; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TULAREMIA; AEROSOL; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; FRANCISELLA TULARENSIS; IMMUNOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AEROSOLS; ANIMALS; FEMALE; FRANCISELLA TULARENSIS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TULAREMIA;

EID: 84945530588     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-015-2022-2     Document Type: Article

References (63)

1. Dienst Jr FT. Tularemia: a perusal of three hundred thirty-nine cases. J La State Med Soc. 1963;115:114-27.
2. Thomas LD, Schaffner W. Tularemia pneumonia. Infect Dis Clin North Am. 2010;24(1):43-55.
3. Bosio CM, Bielefeldt-Ohmann H, Belisle JT. Active suppression of the pulmonary immune response by Francisella tularensis Schu4. J Immunol. 2007;178(7):4538-47.
4. Parsa KV, Butchar JP, Rajaram MV, Cremer TJ, Gunn JS, Schlesinger LS, et al. Francisella gains a survival advantage within mononuclear phagocytes by suppressing the host IFNgamma response. Mol Immunol. 2008;45(12):3428-37.
5. Bosio CM, Dow SW. Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J Immunol. 2005;175(10):6792-801.
6. Chase JC, Celli J, Bosio CM. Direct and indirect impairment of human dendritic cell function by virulent Francisella tularensis Schu S4. Infect Immun. 2009;77(1):180-95.
7. Melillo AA, Bakshi CS, Melendez JA. Francisella tularensis antioxidants harness reactive oxygen species to restrict macrophage signaling and cytokine production. J Biol Chem. 2010;285(36):27553-60.
8. Dotson RJ, Rabadi SM, Westcott EL, Bradley S, Catlett SV, Banik S, et al. Repression of inflammasome by Francisella tularensis during early stages of infection. J Biol Chem. 2013;288(33):23844-57.
9. Mahawar M, Atianand MK, Dotson RJ, Mora V, Rabadi SM, Metzger DW, et al. Identification of a novel Francisella tularensis factor required for intramacrophage survival and subversion of innate immune response. J Biol Chem. 2012;287(30):25216-29.
10. Ireland R, Wang R, Alinger JB, Small P, Bosio CM. Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8. J Immunol. 2013;191(3):1276-86.
11. Barker JR, Klose KE. Molecular and genetic basis of pathogenesis in Francisella tularensis. Ann N Y Acad Sci. 2007;1105:138-59.
12. Horzempa J, O'Dee DM, Shanks RM, Nau GJ. Francisella tularensis DeltapyrF mutants show that replication in nonmacrophages is sufficient for pathogenesis in vivo. Infect Immun. 2010;78(6):2607-19.
13. Andersson H, Hartmanova B, Ryden P, Noppa L, Naslund L, Sjostedt A. A microarray analysis of the murine macrophage response to infection with Francisella tularensis LVS. J Med Microbiol. 2006;55(Pt 8):1023-33.
14. Butchar JP, Cremer TJ, Clay CD, Gavrilin MA, Wewers MD, Marsh CB, et al. Microarray analysis of human monocytes infected with Francisella tularensis identifies new targets of host response subversion. PLoS One. 2008;3(8):e2924.
15. Paranavitana C, Pittman PR, Velauthapillai M, Zelazowska E, Dasilva L. Transcriptional profiling of Francisella tularensis infected peripheral blood mononuclear cells: a predictive tool for tularemia. FEMS Immunol Med Microbiol. 2008;54(1):92-103.
16. Andersson H, Hartmanova B, Back E, Eliasson H, Landfors M, Naslund L, et al. Transcriptional profiling of the peripheral blood response during tularemia. Genes Immun. 2006;7(6):503-13.
17. Andersson H, Hartmanova B, Kuolee R, Ryden P, Conlan W, Chen W, et al. Transcriptional profiling of host responses in mouse lungs following aerosol infection with type A Francisella tularensis. J Med Microbiol. 2006;55(Pt 3):263-71.
18. David J, Gates AJ, Griffiths GD, Lukaszewski RA. Gene expression following low dose inhalational Francisella tularensis (SchuS4) exposure in Balb/c mice and the potential role of the epithelium and cell adhesion. Microbes Infect. 2012;14(4):369-79.
19. Kingry LC, Troyer RM, Marlenee NL, Bielefeldt-Ohmann H, Bowen RA, Schenkel AR, et al. Genetic identification of unique immunological responses in mice infected with virulent and attenuated Francisella tularensis. Microbes Infect. 2011;13(3):261-75.
20. Blankley S, Graham CM, Howes A, Bloom CI, Berry MP, Chaussabel D, et al. Identification of the key differential transcriptional responses of human whole blood following TLR2 or TLR4 ligation in-vitro. PLoS One. 2014;9(5):e97702.
21. Hirotani T, Yamamoto M, Kumagai Y, Uematsu S, Kawase I, Takeuchi O, et al. Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-beta. Biochem Biophys Res Commun. 2005;328(2):383-92.
22. Seok J, Xiao W, Moldawer LL, Davis RW, Covert MW. A dynamic network of transcription in LPS-treated human subjects. BMC Syst Biol. 2009;3:78.
23. Walters KA, Olsufka R, Kuestner RE, Cho JH, Li H, Zornetzer GA, et al. Francisella tularensis subsp. tularensis induces a unique pulmonary inflammatory response: role of bacterial gene expression in temporal regulation of host defense responses. PLoS One. 2013;8(5):e62412.
24. Hajjar AM, Harvey MD, Shaffer SA, Goodlett DR, Sjostedt A, Edebro H, et al. Lack of in vitro and in vivo recognition of Francisella tularensis subspecies lipopolysaccharide by Toll-like receptors. Infect Immun. 2006;74(12):6730-8.
25. Sender V, Stamme C. Lung cell-specific modulation of LPS-induced TLR4 receptor and adaptor localization. Commun Integr Biol. 2014;7:e29053.
26. Ho Sui SJ, Fulton DL, Arenillas DJ, Kwon AT, Wasserman WW. oPOSSUM: integrated tools for analysis of regulatory motif over-representation. Nucleic Acids Res. 2007;35(Web Server issue):W245-252.
27. Ho Sui SJ, Mortimer JR, Arenillas DJ, Brumm J, Walsh CJ, Kennedy BP, et al. oPOSSUM: identification of over-represented transcription factor binding sites in co-expressed genes. Nucleic Acids Res. 2005;33(10):3154-64.
28. Hol J, Wilhelmsen L, Haraldsen G. The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade bodies. J Leukoc Biol. 2010;87(3):501-8.
29. Kobayashi Y. The role of chemokines in neutrophil biology. Front Biosci. 2008;13:2400-7.
30. Husebye H, Aune MH, Stenvik J, Samstad E, Skjeldal F, Halaas O, et al. The Rab11a GTPase controls Toll-like receptor 4-induced activation of interferon regulatory factor-3 on phagosomes. Immunity. 2010;33(4):583-96.
31. Chong A, Wehrly TD, Nair V, Fischer ER, Barker JR, Klose KE, et al. The early phagosomal stage of Francisella tularensis determines optimal phagosomal escape and Francisella pathogenicity island protein expression. Infect Immun. 2008;76(12):5488-99.
32. Medina EA, Morris IR, Berton MT. Phosphatidylinositol 3-kinase activation attenuates the TLR2-mediated macrophage proinflammatory cytokine response to Francisella tularensis live vaccine strain. J Immunol. 2010;185(12):7562-72.
33. Parsa KV, Ganesan LP, Rajaram MV, Gavrilin MA, Balagopal A, Mohapatra NP, et al. Macrophage pro-inflammatory response to Francisella novicida infection is regulated by SHIP. PLoS Pathog. 2006;2(7):e71.
34. Clemens DL, Lee BY, Horwitz MA. Virulent and avirulent strains of Francisella tularensis prevent acidification and maturation of their phagosomes and escape into the cytoplasm in human macrophages. Infect Immun. 2004;72(6):3204-17.
35. Gillette DD, Curry HM, Cremer T, Ravneberg D, Fatehchand K, Shah PA, et al. Virulent Type A Francisella tularensis actively suppresses cytokine responses in human monocytes. Front Cell Infect Microbiol. 2014;4:45.
36. Crane DD, Ireland R, Alinger JB, Small P, Bosio CM. Lipids derived from virulent Francisella tularensis broadly inhibit pulmonary inflammation via toll-like receptor 2 and peroxisome proliferator-activated receptor alpha. Clin Vaccine Immunol. 2013;20(10):1531-40.
37. Broekhuijsen M, Larsson P, Johansson A, Bystrom M, Eriksson U, Larsson E, et al. Genome-wide DNA microarray analysis of Francisella tularensis strains demonstrates extensive genetic conservation within the species but identifies regions that are unique to the highly virulent F. tularensis subsp. tularensis. J Clin Microbiol. 2003;41(7):2924-31.
38. Cremer TJ, Ravneberg DH, Clay CD, Piper-Hunter MG, Marsh CB, Elton TS, et al. MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced pro-inflammatory cytokine response. PLoS One. 2009;4(12):e8508.
39. Ludwig JW, Richards ML. Targeting the secretory pathway for anti-inflammatory drug development. Curr Top Med Chem. 2006;6(2):165-78.
40. Rougerie P, Miskolci V, Cox D. Generation of membrane structures during phagocytosis and chemotaxis of macrophages: role and regulation of the actin cytoskeleton. Immunol Rev. 2013;256(1):222-39.
41. Skarp KP, Vartiainen MK. Actin on DNA-an ancient and dynamic relationship. Cytoskeleton. 2010;67(8):487-95.
42. Man SM, Ekpenyong A, Tourlomousis P, Achouri S, Cammarota E, Hughes K, et al. Actin polymerization as a key innate immune effector mechanism to control Salmonella infection. Proc Natl Acad Sci U S A. 2014;111(49):17588-93.
43. Haglund CM, Welch MD. Pathogens and polymers: microbe-host interactions illuminate the cytoskeleton. J Cell Biol. 2011;195(1):7-17.
44. Trosky JE, Liverman AD, Orth K. Yersinia outer proteins: Yops. Cell Microbiol. 2008;10(3):557-65.
45. Clemens DL, Lee BY, Horwitz MA. Francisella tularensis enters macrophages via a novel process involving pseudopod loops. Infect Immun. 2005;73(9):5892-902.
46. Clemens DL, Lee BY, Horwitz MA. Francisella tularensis phagosomal escape does not require acidification of the phagosome. Infect Immun. 2009;77(5):1757-73.
47. Beutler B. Tlr4: central component of the sole mammalian LPS sensor. Curr Opin Immunol. 2000;12(1):20-6.
48. Chowdhury P, Sacks SH, Sheerin NS. Toll-like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products. Clin Exp Immunol. 2006;145(2):346-56.
49. Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA. Cytoplasmic LPS activates caspase-11: implications in TLR4-independent endotoxic shock. Sci. 2013;341(6151):1250-3.
50. Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Sci. 2013;341(6151):1246-9.
51. Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? J Leukoc Biol. 2010;87(6):989-99.
52. Hall JD, Woolard MD, Gunn BM, Craven RR, Taft-Benz S, Frelinger JA, et al. Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112. Infect Immun. 2008;76(12):5843-52.
53. Moreland JG, Hook JS, Bailey G, Ulland T, Nauseef WM. Francisella tularensis directly interacts with the endothelium and recruits neutrophils with a blunted inflammatory phenotype. Am J Physiol Lung Cell Mol Physiol. 2009;296(6):L1076-1084.
54. Armstrong L, Medford AR, Uppington KM, Robertson J, Witherden IR, Tetley TD, et al. Expression of functional toll-like receptor-2 and -4 on alveolar epithelial cells. Am J Respir Cell Mol Biol. 2004;31(2):241-5.
55. Menden H, Tate E, Hogg N, Sampath V. LPS-mediated endothelial activation in pulmonary endothelial cells: role of Nox2-dependent IKK-beta phosphorylation. Am J Physiol Lung Cell Mol Physiol. 2013;304(6):L445-455.
56. Thorley AJ, Grandolfo D, Lim E, Goldstraw P, Young A, Tetley TD. Innate immune responses to bacterial ligands in the peripheral human lung--role of alveolar epithelial TLR expression and signalling. PLoS One. 2011;6(7):e21827.
57. Skerrett SJ, Liggitt HD, Hajjar AM, Wilson CB. Cutting edge: myeloid differentiation factor 88 is essential for pulmonary host defense against Pseudomonas aeruginosa but not Staphylococcus aureus. J Immunol. 2004;172(6):3377-81.
58. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M, et al. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 1998;9(1):143-50.
59. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Sci. 2003;301(5633):640-3.
60. Conlan JW, KuoLee R, Shen H, Webb A. Different host defences are required to protect mice from primary systemic vs pulmonary infection with the facultative intracellular bacterial pathogen, Francisella tularensis LVS. Microb Pathog. 2002;32(3):127-34.
61. Faith SA, Smith LP, Swatland AS, Reed DS. Growth conditions and environmental factors impact aerosolization but not virulence of Francisella tularensis infection in mice. Front Cell Infect Microbiol. 2012;2:126.
62. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2002;30(1):207-10.
63. Yang S, Rothman RE, Hardick J, Kuroki M, Hardick A, Doshi V, et al. Rapid polymerase chain reaction-based screening assay for bacterial biothreat agents. Acad Emerg Med. 2008;15(4):388-92.